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Objective: The goal of the Asian Pharmacoepidemiology Network is to study the effective-
ness and safety of medications commonly used in Asia using databases from individual Asian 
countries. An efficient infrastructure to support multinational pharmacoepidemiologic studies 
is critical to this effort.
Study design and setting: We converted data from the Japan Medical Data Center database, 
Taiwan’s National Health Insurance Research Database, Hong Kong’s Clinical Data Analysis 
and Reporting System, South Korea’s Ajou University School of Medicine database, and the 
US Medicare 5% sample to the Observational Medical Outcome Partnership common data 
model (CDM).
Results: We completed and documented the process for the CDM conversion. The coordinat-
ing center and participating sites reviewed the documents and refined the conversions based 
on the comments. The time required to convert data to the CDM varied widely across sites and 
included conversion to standard terminology codes and refinements of the conversion based on 
reviews. We mapped 97.2%, 86.7%, 92.6%, and 80.1% of domestic drug codes from the USA, 
Taiwan, Hong Kong, and Korea to RxNorm, respectively. The mapping rate from Japanese 
domestic drug codes to RxNorm (70.7%) was lower than from other countries, and we mapped 
remaining unmapped drugs to Anatomical Therapeutic Chemical Classification System codes. 
Because the native databases used international procedure coding systems for which mapping 
tables have been established, we were able to map >90% of diagnosis and procedure codes to 
standard terminology codes.
Conclusion: The CDM established the foundation and reinforced collaboration for multina-
tional pharmacoepidemiologic studies in Asia. Mapping of terminology codes was the greatest 
challenge, because of differences in health systems, cultures, and coding systems.
Keywords: clinical coding, computer communication networks, feasibility studies, pharma-
coepidemiology, pharmacovigilance
Introduction
Multinational pharmacoepidemiologic studies provide opportunities to compare 
medication use and effects and to enhance collaboration across countries.1 With 
advances in technology and informatic methods, studies using multiple databases 
covering a large number of patients across multiple countries have become more 
feasible.2 Because of concerns about data privacy and related ethical issues, a distrib-
uted network approach using a common data model (CDM) is preferred. Each data 
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site converts native databases to a common data format and 
performs analyses by executing common analytic programs 
created by a coordinating center. This approach is optimal 
for producing high-quality, flexible, efficient analyses while 
preserving data privacy.2,3
The Asian Pharmacoepidemiology Network (AsPEN) 
is the first multinational research network in Asia. It was 
founded in 2008 to support the conduct of multinational 
pharmacoepidemiologic studies in the Asia-Pacific region.4 
AsPEN investigators have completed several pharmacoepi-
demiologic studies by creating study-specific CDMs based 
on a common study protocol.5–7 However, this approach is 
inefficient. Therefore, the investigators collaborated with 
the Observational Medical Outcome Partnership (OMOP)8 
to initiate the Surveillance of Health Care in Asia Network 
(SCAN) in May 2013, which converts domestic databases 
in Asian countries to a global CDM to reinforce the multi-
national research infrastructure for future studies.2
However, converting databases from Asian countries can 
be more challenging than converting databases from North 
America and Europe, because of greater differences across 
health care systems, cultures, and languages.1 We describe the 
processes and quality of data extraction, transformation, and 
load (ETL) from participating databases to a CDM, which is 
the cornerstone of SCAN. We describe the unique opportuni-
ties and challenges of applying a CDM to Asian databases.
Methods
Participating countries and databases
We converted the following five health care databases to a 
CDM: the Japan Medical Data Center (JMDC) database, the 
National Health Insurance Research Database (NHIRD) from 
Taiwan, the Clinical Data Analysis and Reporting System 
(CDARS) database from Hong Kong, the Ajou University 
School of Medicine (AUSOM) database from South Korea, 
and the Medicare database from the United States.2 Details 
of each database have been described elsewhere.2 In brief, 
the NHIRD is a national claims’ database covering the entire 
population of Taiwan, from which we obtained a random 
sample of ~1 million subjects selected by 2005.9 We included 
two national claims’ databases covering specific groups: the 
JMDC database, which covers a sample of employees and 
their dependents from the universal health care system in 
Japan, and a 5% random sample of data from the US Medi-
care program, which covers residents of the USA 65 years 
and older, younger persons with disabilities, and persons with 
end-stage renal disease. We included a national electronic 
health record, the CDARS, which covers all public hospitals 
and their outpatient clinics in Hong Kong. In addition, we 
included electronic health records from the AUSOM, which 
operates a tertiary teaching hospital in South Korea with 
1096 patient beds and 23 operating rooms. The features of 
these databases are summarized in Table 1.
CDM
The OMOP CDM is designed to standardize format (eg, data 
structure) and semantics (eg, terminology codes for medical 
concepts and coded values) of various observational data, 
including health care utilization data and electronic health 
record data.8,10,11 We used version 4 of the CDM, which con-
tains 18 data tables, including a table for patient demographic 
characteristics and health care information, such as diagnosis, 
medications, and procedures. Studies of the validity of apply-
ing the CDM to observational electronic databases have been 
published elsewhere.3,8,12,13
Conversion of data and mapping of 
terminology
Each site converted its data to the CDM using published 
specifications.8 The first step was to map all terminology 
codes from the domestic databases to the common termi-
nology codes for the CDM: the RxNorm system from the 
US National Library of Medicine for medications;14 the 
Systematized Nomenclature of Medicine – Clinical Terms 
(SNOMED-CT) from the SNOMED International for con-
ditions and diagnoses;15 and International Classification of 
Diseases, Ninth Revision (ICD-9) procedure codes, Current 
Procedural Terminology, Fourth Edition (CPT-4) codes, and 
Healthcare Common Procedure Coding System codes for 
procedures. We used Logical Observation Identifiers Names 
and Codes (LOINC) for observational data from the South 
Korean medical center.
Because most of the domestic databases used their own 
domestic coding systems for medications,2 we mapped all 
domestic drug codes by using the generic name, strength, 
and administration dosage form of the medicinal product, 
with the exception of the mapping between US National 
Drug Codes and RxNorm, for which a mapping table was 
already available.8,14 All participating databases used ICD-9 
or the International Classification of Diseases, Tenth Revi-
sion (ICD-10) for conditions. The table for mapping ICD-9 
and ICD-10 codes to SNOMED-CT was created by the 
OMOP.8,14 Other terminology codes, such as patients’ demo-
graphic characteristics (eg, sex and race), were also mapped 
to common terminology codes (eg, HL7 Administrative Sex 
and CDC Race). Other terminology codes used in the CDM 
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Table 1 Databases included in SCAN and their features
Database type and featuresa Databases 
participating in 
SCAN
Remainder databases from AsPEN 
with similar features (potential 
candidates)
National claims databases covering entire populations
Representativeness to entire
population
Nonclinical
information
Clinical
information
Longitudinal pattern
Standard
terminology
Follow-up
of sample
0
1
2
3
NHIRD (Taiwan) HIRA (South Korea)
National claims databases covering specific populations
Representativeness to entire
population
Nonclinical
information
Clinical
information
Longitudinal pattern
Standard
terminology
Follow-up
of sample
0
1
2
3
JMDC (Japan) and 
Medicare databases 
(USA)
DVA database (Australia)
National electronic health records covering entire populations
Representativeness to entire
population
Nonclinical
information
Clinical
information
Longitudinal pattern
Standard
terminology
Follow-up
of sample
0
1
2
3
CDARS (Hong Kong) NEHR (Singapore)
One-hospital databases
Representativeness to entire
population
Nonclinical
information
Clinical
information
Longitudinal pattern
Standard
terminology
Follow-up
of sample
0
1
2
3
AUSOM (South Korea) Buddhachinaraj Hospital Database 
(Thailand) or HIS-WCH (China) and most 
electronic health records from hospitals in 
Asia
Notes: a We used radar charts to quantify the features of the databases. Point 3 indicates well, Point 2 indicates good, and Point 1 indicates poor. For example, national 
claims databases such as Taiwan’s NHIRD are highly representative of the entire population and have strong follow-up of the sample but lack some clinical information such 
as laboratory data and nonclinical information such as socioeconomic status. Conversely, electronic health records have more clinical details, but they are generally stored 
in a nonstandard manner or by free text.
Abbreviations: AsPEN, Asian Pharmacoepidemiology Network; AUSOM, Ajou University School of Medicine; CDARS, Clinical Data Analysis and Reporting System; DVA, 
Department of Veterans’ Affairs; HIRA, Health Insurance Review and Assessment; HIS-WCH, Hospital Information System of West China Hospital; JMDC, Japan Medical 
Data Center; NEHR, National Electronic Health Record; NHIRD, National Health Insurance Research Database; SCAN, Surveillance of Health Care in Asia Network.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.6
1.
25
 o
n 
22
-A
ug
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
878
Lai et al
are described in the specifications.8 The mapping tables 
from Observational Health Data Sciences and Informatics 
(OHDSI) are publicly available from the website of ATHENA 
standardized vocabularies at http:\\www.athena.ohdsi.org.
Quality assurance
The participating sites were required to record all conversion 
processes in ETL documents for review by the coordinating 
center and the sites.8 The ETL documents from the five sites 
are included in the Supplementary materials. We analyzed 
the mapping rates between common terminology codes and 
domestic codes to assess the integrity of the data (Figure 1). 
At least two experts from each site with both a pharmacology 
background and sufficient English skills for the terminology 
for medications reviewed the mapping manually to confirm 
the accuracy. In addition, we performed Observational Source 
Characteristics Analysis Report (OSCAR) assessments. 
OSCAR is a SAS program that provides structured output of 
descriptive statistics for all relevant tables in the converted 
CDM to facilitate evaluation of the quality of conversion.8 The 
OSCARs were distributed and reviewed by the sites and the 
coordinating center. The details of the OSCAR assessments 
were publicly available.8 The refinements of the conversions 
were based on monthly teleconferences and quality assess-
ments; additional conference calls were also organized, if 
required, to identify and implement refinements and resolve 
Figure 1 Rates of mapping on terminology codes.
Notes: We included the AUSOM database from Korea, the CDARS from Hong Kong, the NHIRD from Taiwan, the JMDC database from Japan, and the Medicare database 
from the USA. The common terminology codes included HCPCS codes, ICD-9 procedure codes, CPT-4 codes, SNOMED-CT, RxNorm produced by the US National Library 
of Medicine, the World Health Organization’s ATC Classification System codes, and LOINC.
Abbreviations: ATC, Anatomical Therapeutic Chemical; AUSOM, Ajou University School of Medicine; CDARS, Clinical Data Analysis and Reporting System; CPT-4, 
Current Procedural Terminology, fourth edition; HCPCS, Healthcare Common Procedure Coding System; ICD-9, International Classification of Diseases, ninth revision; JMDC, 
Japan Medical Data Center; LOINC, Logical Observation Identifiers Names and Codes; NHIRD, National Health Insurance Research Database; SNOMED-CT, Systematized 
Nomenclature of Medicine – Clinical Terms.
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issues. We locked the data after completion of the conversion 
and quality checks. All sites used SAS Version 9.3 (SAS 
Institute Inc., Cary, NC, USA) for conversion as well as the 
analysis.
The study was approved by the institutional review 
board of each site, including the Duke University Health 
System (USA), the Public Health Research Foundation 
(Japan; # 4B0001), the National Cheng-Kung Univer-
sity Hospital ( Taiwan; B-EX-102-003), the University 
of Hong Kong/Hospital Authority Hong Kong West 
Cluster (# UW13-504), and Ajou University (Korea; 
AJIRB-MED-MDB-14-078).
Results
Database conversions
It took up to 13 months to convert the data from each site to 
the initial version of the CDM and ~17 months for refine-
ments. We unlocked the data to update the conversion when 
code mappings were refined or updated. We recorded all of the 
conversion processes in the ETL documents (Supplementary 
materials). The coordinating center and  participating sites 
reviewed the ETL documents and refined the  conversions 
based on the comments. Figure 2 is a schematic presentation 
of ETL, showing which data components from the partici-
pating databases were converted to the CDM. For example, 
Conditions
Prescribing
doctors
Service
provider
Membership
and
membership
history
Person
Death
Location
Observed period
Payer plan period
Beneficiary
summary
Hospice
Home health agency
Skilled nursing facility
Part D drug event
Inpatient
Outpatient
Carrier
Durable medical
equipment
JMDC
Source tables
Demographics and eligibility
Medicare
source tables
Provider
Organization
Care site
Location
Visit occurence
Condition occurence
Condition era
Drug exposure
Drug era
Procedure occurrence
Drug cost
Procedure cost
Health care provider and facility
Exposure and outcome
Health expenditure
Drugs from
hospital/clinic
Claims from
hospital/clinic
Patients in
claims
Medical
procedures
Drugs from
community
pharmacy
Claims from
community
pharmacy
Drug cost
A
Figure 2 (Continued)
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the person table in the CDM primarily contains information 
about patients’ demographic characteristics and was converted 
based on the Beneficiary Summary File of the US Medicare 
database, the Registry for Beneficiaries File of the NHIRD, the 
Membership/History File of the JMDC, and the three episode 
files of the CDARS (ie, Outpatient Episode, Inpatient Episode, 
and Accident and Emergency Episode). Taiwan and Hong 
Kong have single-payer national health insurance systems, 
and Japan has a multipayer national health insurance system 
that covers most of the relevant medical costs; however, the 
Medicare program offers diverse insurance coverage (eg, 
Medicare Parts A, B, and D) and medication expenses may 
not be covered for beneficiaries who are not enrolled in Part 
D. Information about eligibility categories was preserved in 
the payer plan periods table in the CDM (Figure 2).
Quality assurance
Conversion to the CDM did not materially affect the integ-
rity of the data (refer to the Supplementary materials, which 
includes a snapshot of the interactive software that visualized 
the descriptive statistics by OSCAR to facilitate the review 
process), as the characteristics of the converted data were 
similar to the characteristics of the domestic databases.
The mapping rates for the condition codes were very high 
(Figure 1). We mapped ~83.4%, 97.9%, and 93.4% of ICD-9 
codes in the Medicare, NHIRD, and CDARS databases to 
SNOMED-CT, respectively. The mapping rates from ICD-
10 in the JMDC and AUSOM databases to SNOMED-CT 
were 99.5% and 99.9%, respectively. The mapping rates for 
the medication codes were also robust; we mapped 97.2% of 
US, 86.7% of Taiwanese, and 80.1% of Korean domestic drug 
Drug
Outpatient
episode
Inpatient
episode
Accident and
emergency
episode
Person
Death
Location
Observed period
Payer plan period
Registry for
beneficiaries (ID)
B
Registry for
contracted medical
facilities (HOSB)
Ambulatory care
expenditures by
visits (CD)
Inpatient
expenditures by
admissions (DD)
Details of
ambulatory care
orders (OO)
Details of inpatient
orders (DO)
CDARS
source tablesDemographics and eligibility
NHIRD
source tables
Provider
Organization
Care site
Location
Visit occurence
Condition occurence
Condition era
Drug exposure
Drug era
Procedure occurrence
Drug cost
Procedure cost
Health care provider and facility
Exposure and outcome
Health expenditure
Diagnosis
Procedure
Figure 2 (Continued)
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codes to RxNorm. The mapping rate from Japanese national 
drug codes to RxNorm was relatively lower than other coun-
tries (70.7%); we mapped the remaining medications to Ana-
tomical Therapeutic Chemical (ATC) Classification System 
codes (28.2%). The mapping rate of Hong Kong’s domestic 
drug codes was only 55.1%. We further broke down the com-
bination products to the ingredient level for this conversion, 
and the mapping improved to 92.6%. The mapping rates for 
demographic characteristics were 100% for all databases.
Discussion
A distributed network approach with a CDM protects data 
confidentiality and facilitates the standardization, efficiency, 
and quality of analyses across data sources from mul-
tiple Asian sites conforming to high scientific standards.1,2 
Although several databases are currently available in Asian 
countries, they have different structures and formats and use 
different terminology codes.2 As a result, the SCAN objective 
to convert data to a CDM is at the foundation of multinational 
pharmacoepidemiologic studies and reinforces the pharma-
coepidemiology and pharmacovigilance system in Asian 
countries.2 We discuss major challenges in Asian databases 
and possible solutions, including the format (eg, data struc-
ture) and content (eg, vocabularies) of conversion. We also 
discuss the opportunities provided by SCAN and the CDM 
for improving pharmacoepidemiology in Asian countries.
Figure 2 Concepts of conversion from participating databases to the common data model.
Notes: (A) Conversions from the Medicare and JMDC source tables. (B) Conversions from the NHIRD and CDARS source tables. (C) Conversions from the Korean 
database source tables. The colors represent different domains of the common data model.
Abbreviations: Carr, carrier; CDARS, Clinical Data Analysis and Reporting System; DME, durable medical equipment; HHA, home health agency; HSP, hospice; IP, inpatient; 
JMDC, Japan Medical Data Center; NHIRD, National Health Insurance Research Database; OP, outpatient; PDE, part D drug event; SNF, skilled nursing facility.
Person
Death
Location
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information
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information
Patient
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history
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Procedure
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Challenges: preparations of the databases
This is a multinational collaborative study involving five 
institutions in Asia and the USA. Effective communication is 
the foundation of a successful collaboration. However, while 
we very much enjoyed and learned from our collaboration, 
effective and timely communication was also challenging 
because of differences in language, time, culture, research 
environments, and health care systems among countries. 
We spent a total of 30 months on the project, and substantial 
efforts and time were spent on understanding the nature of the 
involved databases, particularly the capability and population 
coverage of each database, and local health care system and 
clinical practices. In a few countries where there was a data 
access constraint, it was very time consuming to retrieve data 
from the source data warehouse before the mapping could be 
carried out. Data privacy was also a significant issue in Asia. 
The study of the databases had to be reviewed by the institu-
tional review board from each site, and we encountered serious 
concerns about potential data disclosures outside the country.
Challenges: conversions to the CDM
The CDM accommodated storage of source data for analyti-
cal needs, with the exception of medical cost and expenditure 
data. Challenges with cost and expenditure data resulted from 
the diversity of health systems across countries. For example, 
Taiwan, Hong Kong, and Korea have single-payer systems; 
Japan has multiple payers in its national health insurance 
system; and the USA has diverse coverage in its Medicare 
program. These differences made conversion of tables for 
health expenditures complicated. Cross-national compari-
sons of health expenditures must also account for currency 
conversions and adjustments to the consumer price index. In 
addition, different insurance systems cover different health 
care items and medical products, making information about 
total payments relatively uninformative.2 Moreover, itemized 
medical expenditures were not available in some databases. 
Many categories of health expenditures were specific to 
countries; for example, there is no concept of a copayment 
and deductible in Japan and the coinsurance and amount 
paid by the payer are a fixed percentage, which differs from 
some other countries. Conversion of cost information will 
require careful thought and refinement and was not ready for 
the SCAN analyses.
Challenges: mapping to common 
terminology codes
Mapping between domestic terminology codes to common 
terminology codes was the major challenge of the conversion 
effort, especially for medications. Because most databases 
used a domestic coding system (eg, US National Drug 
Codes), the formula of medications differed across countries. 
The domestic databases also included a large amount of free-
text information in local languages, which made the process 
of refining the mapping for medication codes more difficult. 
Manual review by experts from participating countries was 
a time-consuming step, but it was worthwhile because the 
quality of conversion largely relied on good mapping. We also 
found it useful to execute automated mapping using generic 
name, strength, and administration dosage as the primary 
step before initiating manual processes.
We successfully mapped ~71%, 87%, and 93% of drug 
codes to RxNorm from Japan, Taiwan, and Hong Kong, 
respectively. Because the medication mapping rate was 
relatively lower in Japan than in other countries, we mapped 
Japanese national drug codes to ATC codes16 to preserve 
information. We found that 31% of unmapped Japanese 
drug codes could be classified as ATC code V03 (all other 
therapeutic products), followed by 8% classified as code B05 
(blood substitutes and perfusion solutions), 4% as code A02 
(medications for acid related disorders), and 3% as code V07 
(all other nontherapeutic products). Because all of Taiwan’s 
drug codes had been mapped to ATC codes before SCAN, 
this information facilitated mapping between Taiwan drug 
codes and RxNorm. We found that most unmapped products 
in Taiwan’s NHIRD were medications for cold or cough 
(28%) and vitamin products (25%) (Table S1 is an example of 
analysis of unmapped medication codes in Taiwan’s NHIRD). 
The major challenge for medication mapping in CDARS was 
for combination products. We separated combination prod-
ucts into individual ingredients, and the mapping improved 
substantially from ~55% to 93%. Evaluation of unmapped 
codes in the domestic databases provided information on 
their impacts. For example, although the unmapped rate of 
medication codes from Taiwan was 20%, they only existed 
in the NHIRD for ~13% of all drug claims in the NHIRD; 
the unmapped rate of medication codes from USA was 72%, 
but they only accounted for 2.8% of ~490 million medication 
claims in the Medicare data. In contrast, because we were 
unable to map many medication codes to the product level 
in Hong Kong’s CDARS and Japan’s JMDC, future analyses 
using the CDM may be limited to those studies that evaluate 
medications at the ingredient level. The vocabularies main-
tained by OHDSI are actively evolving, so results in this 
article reflect the findings from a particular version, which 
may have changed in subsequent versions. In particular, 
OHDSI recently released an RxNorm Extension vocabulary 
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to improve the ability of non-US sources to map source drug 
codes to standard concepts while preserving information 
about ingredient, brand, strength, and formulation.
The system of Chinese herbal products differs from 
Western medicine – for example, the classification of single 
herbal products and herbal formulas and considerations about 
origin, morphology, active ingredients, and mechanisms of 
function.17 There is no common terminology coding system 
for Chinese herbal products. We preserved information about 
these products from the domestic codes or text in the CDM. 
There is a need for a different approach to capture Chinese 
herbal product information completely for future studies. 
Although it would require a painstaking effort to develop 
the coding system, the ability to study the safety of Chinese 
herbal products is indispensable in the Asian pharmacoepi-
demiology and pharmacovigilance system.
Mapping for conditions and procedures
Mapping for conditions and procedures had far fewer chal-
lenges, because the participating databases used either ICD-9 
codes or ICD-10 codes for conditions and international 
procedure coding systems for which mapping tables have 
been established.8,14 Although the mapping rate of conditions 
in the USA was only 83.4%, we found that the unmapped 
codes were predominantly invalid codes (65%) belonging to 
ICD-9 supplementary classifications (codes V01–V89 and 
E800–E999). The primary challenge of mapping procedures 
arose from the Taiwan NHIRD’s use of domestic procedure 
codes as the primary codes for reimbursement. To maintain 
data integrity, we undertook an extra mapping of Taiwan’s 
domestic procedure codes to ICD-9 procedure codes using 
the mapping tables provided by Taiwan’s National Health 
Insurance Administration,9 which resulted in the coding of 
>300,000 records per year for procedures in the NHIRD. 
Although there were 18.9% unmapped codes remaining, we 
found that most of them were classified as excision, recon-
struction, biopsy, and health education, and we felt that these 
would have a relatively minor impact on international stud-
ies because most of them were country-specific procedures 
for reimbursement. The mapping rates for procedure codes 
in Medicare, JMDC, and CDARS were relatively high, and 
most unmapped procedures were nonsurgical and noninva-
sive procedures such as laboratory tests, radiology or imag-
ing, and physiological examinations. Data in the procedure 
domain are particularly challenging because there is no 
single comprehensive vocabulary that reflects all procedures 
administered by providers in the health care system. Thus, 
multiple vocabularies (including CPT-4, ICD-9/-10 PCS, 
LOINC, and SNOMED-CT) are required to cover the land-
scape. Where the vocabularies have overlapping concepts, 
attempts have been made to map between vocabularies in the 
OHDSI vocabularies. In the current stage, a researcher will 
need to explicitly select codes from all standard procedure 
terminologies.
Although it is not possible to convert data to the CDM 
without loss of some information, because no model cov-
ers all situations in all countries, use of the current version 
of the CDM for AsPEN multinational studies is feasible as 
long as the investigators understand the model. The OSCAR 
outputs reflected good consistency in characteristic statistics 
between domestic and converted databases. The SCAN results 
compared favorably to previous studies, indicating both good 
quality and applicability of the CDM as well as scientific 
reproducibility. The CDM preserved all relevant information 
from domestic databases in the source fields whenever fields 
in the source database could not be accommodated. Investiga-
tors should review the ETL documents carefully to understand 
what information was lost in conversion to prevent the misclas-
sification of exposures or outcomes measured and to use the 
source fields if required. We believe that continuously updating 
the CDM and refining the conversions are critical. Locking 
the CDM is advisable unless refinement is required to avoid 
discrepancies of the versions analyzed among participants.
Opportunities for multinational 
pharmacoepidemiologic studies
Multinational pharmacoepidemiologic studies provide 
opportunities to compare medication use and effects across 
countries.1 SCAN demonstrated the feasibility and efficiency 
of studying racial and ethnic differences in medical product 
use and effects, as the CDM could apply to most routine 
pharmacoepidemiologic studies by using common software 
or analytical programs and maintaining data privacy with 
transparent and scientific standards.2,10,18,19 Because some 
information was stored by free text or without consistent 
definitions in the domestic databases, conversion facilitated 
the standardization of terminologies before entry into the 
CDM through review processes to improve the quality of 
analyses. SCAN provides a valuable experience to inform 
future conversions of the remaining databases in AsPEN, 
such as the examples listed in Table 1, and to create better 
environments to evaluate the effects of medical products 
across Asian countries.2 Moreover, because many databases 
from North American and European countries have been 
converted to the CDM,3 SCAN offers the opportunity for 
Asian countries to join worldwide studies that include all 
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databases converted to the CDM. This facilitates the prompt 
identification of issues for medical products among various 
populations to minimize the harms of treatment.
Through SCAN, we gained a better understanding of 
each site and the countries’ health systems and databases and 
also enhanced collaboration among countries during study 
communications.1 We understood the cultural factors that 
influenced prescribing or coding behaviors. We were able to 
discuss the challenges encountered and to come up with bet-
ter approaches to improve the quality of conversions. SCAN 
could also be regarded as the primary step or pilot project to 
encourage future participants for more collaborations.
Conclusion
Conversion of domestic databases to the CDM established a 
foundation for future multinational pharmacoepidemiologic 
studies in AsPEN, which will enable improvements in phar-
macovigilance and pharmacoepidemiology systems in Asian 
countries. We analyzed the quality of the conversions and 
performed analyses to test the applicability and quality of 
the CDM. These results developed strong grounds for future 
studies. The major challenge in SCAN was the mapping of 
terminology codes, especially for medications, which had large 
variety among countries. Future work will involve enriching 
the CDM vocabulary with missing drug concepts to ensure 
full mapping of all codes. SCAN will increase collaboration 
among participating countries. Use of the CDM as the first 
global model for AsPEN offers opportunities to efficiently col-
laborate with data partners in North America and Europe who 
have also converted their databases to the CDM for the conduct 
of international studies through networks such as OHDSI.8,19 
Data partners should continuously maintain the CDM, using 
both the latest community standards for the data schema and 
the most up-to-date versions of the standardized vocabular-
ies in order to ensure that their data are of good quality.8,19 
We anticipate that this successful experience will encourage 
other Asian countries to participate, enabling researchers to 
efficiently and comprehensively undertake pharmacoepide-
miology and pharmacovigilance efforts in Asian populations.
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